MedTrace Logo

Meropenem Pharmacokinetics in Spontaneous Bacterial Peritonitis

NCT03571711 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-08-07

No results posted yet for this study

Summary

The emergence of multidrug-resistant bacteria has increased the use of meropenem in spontaneous bacterial peritonitis (SBP). Additionally, recent studies suggested female gender as an independent risk factor for mortality in SBP. Studies regarding possible sex dependent differences in meropenem pharmacokinetics in SBP are scarce. The aim of this study is to determine the pharmacokinetics of meropenem during SBP in female and male patients with liver cirrhosis to investigate whether pharmacodynamics therapy goals are met.

Conditions

Interventions

DRUG

Meropenem Injection

Meropenem is administered as prescribed by treating physician

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Benjamin Maasoumy, PD Dr. · Hannover Medical School

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2020-07-01
Completion
2021-01-01
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03571711 on ClinicalTrials.gov